Article
Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.
Hepatology (Baltimore, Md.) - 1 Jun 2001
Leung N W, Lai C L, Chang T T, Guan R, Lee C M, Ng K Y, Lim S G, Wu P C, Dent J C, Edmundson S, Condreay L D, Chien R N
Abstract excerpt
A study in Chinese patients with chronic hepatitis B showed that treatment with lamivudine for 1 year significantly improves liver histology and enhances hepatitis B e antigen (HBeAg) seroconversion compared with placebo. Fifty-eight patients from this 1-year study have received long-term treatment with lamivudine 100 mg; the outcome of 3 years of lamivudine is reported here. Before treatment, all patients had...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.